Novo Nordisk, Lilly lobby for Medicare coverage of weight-loss drug, WSJ report

Novo Nordisk (NVO) and Eli Lilly (LLY) are lobbying Congress to grant their new drugs that treat diabetes and obesity access to Medicare coverage, Liz Whyte of The Wall Street Journal reports. Currently, the new drugs are generating huge sales for the companies, but they cost hundreds of dollars a month and are not covered by Medicare. If covered by Medicare, the 65M older and disabled people insured through Medicare could push sales higher. Novo Nordisk’s Wegovy costs more than $10,000 a year without insurance. Reference Link